Evaluation of the Impact of the AVanCer Program Provided by the ARRPAC Day Center

NCT ID: NCT05795686

Last Updated: 2024-06-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

162 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-20

Study Completion Date

2026-04-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In France, more than 150,000 strokes occur each year. Stroke is a major risk factor for dependency, representing the leading cause of acquired non-traumatic disability in adults. Head injuries, which are also very frequent, can leave similar neuropsychiatric sequelae.

These events are brutal and their physical, psychological, emotional, social and financial consequences disrupt the lives of patients and their families. Thanks to improved access to thrombolysis and thrombectomy for the management of acute stroke, the prognosis has been profoundly improved. Nevertheless, the increase in post-stroke survival and the evolution of the type of after-effects require the development of support systems dedicated to these post-stroke patients. The same issues are raised for people who have suffered a head injury with similar consequences that require specialised care.

Currently, health care is well structured for the acute phase and there is an improvement in the provision of care in specialised rehabilitation services, but the dedicated medico-social provision for people returning home remains insufficient despite the significant needs. The ARRPAC association (Accompaniment, Rehabilitation, Respite after Stroke and Cerebral Palsy) is setting up a new comprehensive medico-social support programme in Lyon (AVanCer programme, opening in June 2022) to improve the autonomy and adaptation capacities of patients and to relieve the social and psycho-affective burden of carers. This experimental day centre, which complements functional rehabilitation and recurrence prevention care, offers adults with brain injury sequelae and their carers therapeutic education programmes, adapted physical activity, social and cognitive remediation and therapeutic workshops, as well as a place for patients and their carers to exchange information and listen. To achieve its ambition, ARRPAC and the AVanCer programme must be integrated into the existing support offer, create partnerships with care structures and evaluate its added value to ensure its sustainability. In case of efficiency and demonstrated benefits for patients, carers and the health system, such a structure could be deployed in other territories.

This study evaluates the implementation of the AVanCer programme in terms of its effect on the target audience, participants' experience and implementation according to the REAIM evaluative framework (Reach, Effectiveness, Adoption, Implementation, and Maintenance).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Brain Injury Rehabilitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

* Quantitative approach by monitoring the structure's operating indicators
* Qualitative approach by semi-structured interviews with professionals of the structure

For patients:

* At inclusion:collection of socio-demographic and medical data,Quality of life (QoL) questionnaires,anxiety and depression,autonomy in health,adherence to treatment
* At end of the program:QoL questionnaires,anxiety and depression,autonomy,autonomy in health,adherence to treatment,satisfaction,semi-structured interviews
* 6 months post-program:data on retention and re-hospitalization,QoL questionnaires,anxiety and depression,autonomy in health,adherence to treatment

For caregivers:

* At inclusion:collection of socio-demographic data,QoL questionnaires,anxiety and depression,perceived burden
* At the end of the program:QoL questionnaires,anxiety and depression,perceived burden,semi-structured interviews
* 6 months post-program:data about new support,QoL questionnaires,anxiety and depression,perceived burden
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients of program "AVanCer"

Patients included in program "AVanCer"

Group Type OTHER

Evaluation of program "AVanCer"

Intervention Type OTHER

Evaluation of program AVanCer with quantitative and qualitative approaches

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evaluation of program "AVanCer"

Evaluation of program AVanCer with quantitative and qualitative approaches

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For patients :

* Male or female of legal age
* Patient who has been selected to start the AVanCer program at the ARRPAC center
* Patient who has agreed to participate in the PATIENT assessment component and has signed the consent form
* Patient able to speak and understand French both orally and in writing

For caregivers :

* Male or female of legal age
* Person who has agreed to participate in the CAREGIVING assessment component and has signed the consent form
* Person able to speak and understand French both orally and in writing

Population of the qualitative study :

* Voluntary patients and caregivers who participated in the quantitative part (follow-up by questionnaires)
* Partner professionals: a sample of 10 representatives of ARRPAC partners who referred people for support during the first 12 months, from the following structures: public Medicine, Surgery, Obstetric health institution, private Medicine, Surgery, Obstetric health institution, public Follow-up and Rehabilitation Care institution, private Follow-up and Rehabilitation Care institution, medico-social institution, town professionals and user associations.
* ARRPAC professionals: the 14 ARRPAC professionals involved in the day care centre will be interviewed in a semi-structured manner

Exclusion Criteria

* Pregnant women, parturient or breastfeeding mothers\*
* Persons deprived of their liberty by a judicial or administrative decision
* Persons under psychiatric care
* Persons admitted to a health or social establishment for purposes other than research
* Persons of full age subject to a legal protection measure (guardian, curators)
* Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Accueil de jour ARRPAC

Bron, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Julie Haesebaert, MD

Role: CONTACT

06-51-42-97-43 ext. +33

Anne Termoz

Role: CONTACT

04-27-85-63-00 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Stéphanie Fanara

Role: primary

04-82-90-54-83 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

69HCL22_0638

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Neurothrombectomy France
NCT02880579 COMPLETED
REACT AGAINST STROKE
NCT02846363 COMPLETED